Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

39.69 +1.08 (+2.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,024,075
Open 38.81
Bid (Size) 37.10 (6)
Ask (Size) 40.90 (3)
Prev. Close 38.61
Today's Range 38.49 - 39.75
52wk Range 29.85 - 59.40
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:HALO is showing good growth, while it is not too expensive.
Despite its growth, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains within the realm of affordability. 
Via Chartmill
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill

Performance

YTD
-28.01%
-28.01%
1 Month
+11.55%
+11.55%
3 Month
-2.96%
-2.96%
6 Month
+20.05%
+20.05%
1 Year
-29.05%
-29.05%

More News

Read More
NASDAQ:HALO, an undervalued stock with good fundamentals.
Via Chartmill
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
Via InvestorPlace
Topics Economy
Exposures Economy
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Via InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
Via InvestorPlace
Earnings Scheduled For November 6, 2023
Via Benzinga
Earnings Outlook For Halozyme Therapeutics
Via Benzinga
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Via Chartmill
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune
Via InvestorPlace
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals.
Via Chartmill
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Via Benzinga
NASDAQ:HALO is showing decent growth, but is still valued reasonably.
Via Chartmill
Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Analyst Expectations for Halozyme Therapeutics's Future
Via Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Where Halozyme Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Halozyme Therapeutics
Via Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via Chartmill
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall
Via InvestorPlace
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Via Benzinga
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.